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Vaccine preparations based on the extracellular domain of Her1 protein (Her1-ECD) have demonstrated, in vitro 
and in vivo, a potent antimetastatic effect on EGFR+ Lewis lung carcinoma model, while associated side effects 
were absent. The Her1-ECD is a glycoprotein with a molecular weight of 105 kDa and has 11 potencial sites for 
N-glycosylation. Glycosylation is a post-translational modification that can affect the protein folding, stability, 
regulates protein half-life, immunogenecity, biological activity and other functions. In this work, the N-
glycosylation Her1-ECD was preliminarily characterized by SDS-PAGE, glycan differentiation by lectin and 
normal phase chromatography. Finally, the biological activity of the glycosylated and totally deglycosylated 
Her1-ECD protein was compared. As results were obtained that N-glycosylation profile of Her1-ECD is 
composed of high mannose, hybrid and complex N-glycans types, and Her1-ECD glycosylation modifies the 
humoral immune response, measured as antibody titers, recognition of EGFR in A431 cell line and cell cycle 
arrest.  
 
 
